JFS Wealth Advisors’s Rein Therapeutics RNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.28K Hold
1,590
– – ﹤0.01% 1724
2026
Q2
$1.65K Hold
1,590
– – ﹤0.01% 1664
2026
Q1
$2.07K Hold
1,590
– – ﹤0.01% 1496
2025
Q4
$1.84K Hold
1,590
– – ﹤0.01% 1573
2025
Q3
$1.82K Hold
1,590
– – ﹤0.01% 1461
2025
Q2
$2.23K Hold
1,590
– – ﹤0.01% 1368
2025
Q1
$2.82K Hold
1,590
– – ﹤0.01% 1338
2024
Q4
$3.66K Hold
1,590
– – ﹤0.01% 1243
2024
Q3
$5.63K Hold
1,590
– – ﹤0.01% 1080
2024
Q2
$4.4K Hold
1,590
– – ﹤0.01% 1120
2024
Q1
$10.5K Hold
1,590
– – ﹤0.01% 799
2023
Q4
$4.85K Hold
1,590
– – ﹤0.01% 1069
2023
Q3
$2.42K Hold
1,590
– – ﹤0.01% 1288
2023
Q2
$2.85K Hold
1,590
– – ﹤0.01% 1248
2023
Q1
$1.97K Hold
1,590
– – ﹤0.01% 1372
2022
Q4
$3.77K Hold
1,590
– – ﹤0.01% 1109
2022
Q3
$7K Hold
1,590
– – ﹤0.01% 885
2022
Q2
$8K Hold
1,590
– – ﹤0.01% 850
2022
Q1
$16K Hold
1,590
– – ﹤0.01% 668
2021
Q4
$18K Hold
1,590
– – ﹤0.01% 592
2021
Q3
$32K Buy
+1,590
New +$34.8K ﹤0.01% 478

Other funds holding RNTX

JFS Wealth Advisors's RNTX Position: Q3 2026 in Review

JFS Wealth Advisors held its Rein Therapeutics (RNTX) position steady in Q3 2026 at 1,590 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1724.

JFS Wealth Advisors first reported a position in RNTX in Q3 2021 and has held it in 21 quarters since. The position peaked at $32K in Q3 2021. 64 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

  • JFS Wealth Advisors held 1,590 shares of Rein Therapeutics worth $1.28K as of Q3 2026.
  • JFS Wealth Advisors left its Rein Therapeutics share count unchanged in Q3 2026.
  • Rein Therapeutics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q3 2026, its #1724 holding.
  • JFS Wealth Advisors first reported a position in Rein Therapeutics in Q3 2021 and has held it in 21 quarters since.
  • JFS Wealth Advisors's Rein Therapeutics position peaked at $32K in Q3 2021.
  • 64 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on JFS Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.